Xing-Jie Liang*


Laboratory of Controllable Nanopharmaceuticals, CAS Center for Excellence in Nanoscience and CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, 100190 Beijing, P. R. China; University of Chinese Academy of Sciences, Beijing 100049, P. R. China



The increasing usage of engineered nanoparticles in many medical and consumer products greatly facilitated our daily lives. Due to their easy fabrication, tunable surface modification, and controllable size and shape, nanoparticles have been widely utilized for different biomedical applications, such as drug and gene delivery, imaging purposes, and detection & diagnosis of diseases, etc. Multidrug resistance as clinical obstacle was broadly explored with different molecular mechanisms for clarification, respectively. There is still no significantly clinical improvement so far. Nanotechnology has been widely used in the development of new strategies for drug delivery and cancer therapy. Compared to traditional drug delivery systems, nano-systems have greater potential in many areas, such as multiple targeting functionalization, combined drugs delivery, longer circulation time and systemic control release. Some of these have been translated from the bench to clinical application and approved by the Food and Drug Administration (FDA) for treatment of various cancerous diseases. With further development of biocompatible nanoformulations, it might be possible to design even more promising multiple-responsive nano-systems synergestic for combined drug delivery and efficient cancer therapy in the future. Nanotechnology-based drug delivery is expected to bring new hope for cancer treatment by enhancing anticancer drug efficacy, overcoming drug resistance and reducing drug toxicity. This presentation describes the characteristic features of tumor resistance to classical chemotherapy and their mechanisms with the aid of nanoparticles for the development of newer drug delivery systems to overcome multidrug resistance in vitro and vivo.



This work was supported by the Natural Science Foundation key project (31630027 and 31430031), National Distinguished Young Scholars grant (31225009). The authors also appreciate the support by the ‘‘Strategic Priority Research Program’’ of the Chinese Academy of Sciences, Grant No. XDA09030301 and support by the external cooperation program of BIC, Chinese Academy of Science, Grant No. 121D11KYSB20130006.


Biographic Details

Name: Xing-Jie Liang

Title: Professor

Affiliation, Country: National Center for Nanoscience and Technology of China, P.R.China

Phone: +86-10-82545569

Fax: +86-10-62656765